{"id":"avt04","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Hypertension"},{"rate":"15–25","effect":"Proteinuria"},{"rate":"5–15","effect":"Bleeding/hemorrhage"},{"rate":"5–10","effect":"Thromboembolic events"},{"rate":"1–2","effect":"Gastrointestinal perforation"},{"rate":"15–25","effect":"Fatigue"},{"rate":"10–20","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AVT04 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling molecule that promotes the formation of new blood vessels. By blocking VEGF, the drug prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a biosimilar of Avastin (bevacizumab), it is designed to have comparable efficacy and safety to the reference biologic.","oneSentence":"AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:03.389Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-squamous non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04930042","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-06-03","conditions":"Psoriasis","enrollment":581},{"nctId":"NCT04744363","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-05-25","conditions":"Psoriasis","enrollment":294}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AVT04","genericName":"AVT04","companyName":"Alvotech Swiss AG","companyId":"alvotech-swiss-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}